Bristol Myers Squibb named Cristian Massacesi, previously AstraZeneca's chief medical officer, as its new CMO effective August 1. Massacesi replaces Samit Hirawat, who contributed to launching multiple key drugs including blockbuster Reblozyl and bolstering Bristol Myers’ oncology pipeline through acquisitions and partnerships. Massacesi's experience with AstraZeneca's oncology and rare disease portfolios, including radiopharma and antibody-drug conjugates, positions him to guide Bristol Myers amid challenges from generic competition and upcoming patent expirations on core drugs such as Revlimid and Opdivo. The appointment signals Bristol Myers' commitment to advancing breakthrough therapies under new leadership.